About Us

Strategy

We are focused on bringing to market medical products that meet the needs of specialist physicians and their patients, thereby building a sustainably profitable business that delivers superior returns to shareholders.

Our strategy is to expand our portfolio of marketed specialty pharmaceuticals and interventional oncology products through acquisition, development and commercial activities.

Having established US commercial operations and commenced selling our specialty pharmaceutical products directly from October 2010, we are now scaling up those operations. This will enable us to sell all of our interventional oncology products directly in the US and to commercialise additional products that emerge from our pipeline or from acquisition activities.

Outside of the US our strategy is to work with partners and distributors to register and sell our products. We will keep this under review and will consider direct sales in certain territories where the economics make sense and where we have the right capabilities.

We are actively pursuing an international expansion strategy for our interventional oncology products, in particular in Asia where high infection rates of hepatitis B and C have led to a high incidence of liver cancer.

We are seeking to licence or acquire additional specialist products that we can sell through our existing commercial operations. In July 2011 we acquired US commercial rights to uridine triacetate, an experimental treatment for accidental overexposure to the chemotherapeutic 5-FU which is in its final stages of development by Wellstat Therapeutics Corporation.

Our research and development focus is on products that we can commercialise ourselves. We have submitted a US regulatory application for Voraxaze^® (glucarpidase), an experimental treatment for the rapid and sustained reduction of toxic methotrexate levels due to impaired renal function; if approved, we intend to market glucarpidase ourselves in the US.

We are also developing Varisolve^® (polidocanol endovenous microfoam (PEM)), which is in Phase III trials in the US for the treatment of varicose veins. We plan to market PEM ourselves in the US reimbursed sector.

We are conducting a number of exploratory studies on our interventional bead products and plan to initiate regulatory studies designed to expand the indicated uses for these products.